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Abstract
Purpose Early metabolic response with a decrease in
glucose demand after cytotoxic treatment has been reported
to precede tumor volume shrinkage. However, preclinical
studies report of a very early rise in metabolism, a flare,
following treatment. To elucidate these observations, we
performed an experimental study on early metabolic
response with sequential analysis of metabolic changes.
Methods Three squamous cell carcinoma cell lines and one
nontumorigenic cell line were exposed to cisplatin. The
uptake of the fluorescent glucose analogue 2-NBDG was
examined at days 1–6 using fluorescence microscopy. The
relation between 2-NBDG-uptake and cell survival was
evaluated.
Results The tumor cells exhibited a high uptake of 2-
NBDG, whereas the uptake in the nonmalignant cells was
low. The more cisplatin sensitive cell lines exhibited a more
pronounced metabolic flare than the less sensitive cell line.
Conclusion A metabolic flare was a very early sign of
treatment response and potentially it could be used as an




Positron emission tomography (PET) with 2-deoxy-2-[
18F]
fluoro-D-glucose ([
18F]FDG) as a tracer is a well-established
method to visualize hypermetabolism in cancer. A number of
clinical studies in different types of tumors evaluating
changes in uptake and metabolism of [
18F]FDG with PET
within 1–3 weeks after initiated cytotoxic therapy have
reported a decrease in glucose metabolism as an early sign of
tumor response to therapy. It is observed before any decrease
in actual tumor size as is seen, i.e., in head and neck cancer,
Hodgkin lymphoma, esophageal cancer, and cervical cancer
[1–4]. Experimentally, a rapid metabolic response has been
demonstrated as by Spaepen et al. [5]. A transient metabolic
flare resulting from an increase in tumor metabolism has
been observed on sequential [
18F]FDG-PET scans 7–10 days
after initiating tamoxifen treatment for breast cancer [6, 7].
The metabolic flare was in these studies associated with
response to tamoxifen therapy, indicating that a metabolic
flare reaction is of predictive value.
In the experimental setting, an early flare phenomenon
following initiation of tumor treatment has been seen in
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cell cancer 1–5 days following initiation of chemotherapy
[8–10]. The underlying mechanism of this early metabolic
flare is not understood. The present study was carried out to
examine early metabolic changes on the cellular level in
tumor cell-lines originating from human squamous cell
carcinomas in relation to sensitivity to cytotoxic treatment
with cisplatin. To facilitate the investigation of the flare
phenomenon, we used the fluorescent 2-deoxyglucose (DG)
analogue 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-
2-deoxyglucose (2-NBDG). This fluorescent DG analogue
has been demonstrated to provide an optical marker of
glucose uptake enabling investigation on a cellular level
and may also be easier to handle than radiolabeled FDG in
the experimental setting [11, 12].
Materials and methods
Chemicals
The chemicals used in this study were of analytical grade.
Cisplatin (1 mg/ml) was purchased from Sigma-Aldrich (St.
Louis, Mo., USA). We used cisplatin in a clinically relevant
dose of 10 µM and in a high dose of 50 µM in order to get an
explicit tumor cell effect. The 2-NBDG was purchased from
Invitrogen (Carlsbad, Calif., USA) and 10 μM 2-NBDG was
freshly made on the same day as the experiment using a low
glucose solution of phosphate-buffered saline (PBS) contain-
ing 10–15% Dulbecco’s Modified Eagle Medium (DMEM)
without fetal bovine serum (FBS).
Cell cultures
We used four in-house human cell lines originating from
primary untreated tumors. Each cell line’sd e g r e eo f
sensitivity to cisplatin was known before the experiment.
The cell line LU-HNxSCC-7, originating from a moderate-
ly differentiated head and neck squamous cell carcinoma
(HNSCC), is cisplatin sensitive. The cell line LU-
HNxSCC-24 originating from a well differentiated HNSCC
is also sensitive to cisplatin, but the third tumorigenic cell
line LU-CX-2 originating from a poorly differentiated SCC
of the uterine cervix has a low sensitivity to cisplatin.
Finally, a nontumorigenic cell line with fibroblasts from the
LU-HNxSCC-24 cell line was used.
Experimental design
The cell lines were trypsinised, washed with PBS, replaced
using DMEM and counted using an automated cell counter
(Invitrogen Carlsbad, Calif., USA). Aliquots of 80,000 cells
weretransferredintoflasksandtheflaskswereplacedina cell
incubator at 37°C and 5% CO2 overnight. The next day,
denoted day 0, the cells in six flasks were exposed to 10 μM
cisplatin, the cells in another six flasks were exposed to
50 μM cisplatin and the cells in six flasks were left as
untreated controls. All flasks were then incubated for 1 h at
37°C and 5% CO2 atmosphere after which the medium
containing cisplatin was removed and replaced with DMEM
containing 10% FBS. The flasks were then returned to the
cell incubator, where they were kept at 37°C and at 5% CO2
until monitoring. At days 1, 3 and 6 after cisplatin exposure,
the cells were monitored using fluorescence microscopy. For
each time point, two flasks from the 10 μM cisplatin group,
two flasks from the 50 μM cisplatin group and two flasks
from the control group were observed. Before observation,
all the cells including the controls were exposed to 10 μM 2-
NBDG in PBS as described above. The cells were incubated
at 37°C and 5% CO2 for 1 h, then washed with cold PBS
twice, after which DMEM containing 10% FBS was added
prior to microscopy. The experiment was done in duplicate
for each cell line.
Real-time fluorescence microscopy
The cell cultures were evaluated for fluorescence, morphol-
ogy and survival. Fluorescence microscopy was performed
using a Leitz Orthoplan Microscope equipped with epi-
illuminator and video-triggered stroboscopic illumination
from a xenon arc (X-Strobe X400, PerkinElmer Salem,
Mass., USA). A silicon intensified target camera (VE-1000-
SIT Dage-MTI, Michigan City, Ind., USA) was attached to
the microscope. A Zeiss Achroplan 20X/0.5 W objective
was used for capturing images. A DSP-200 image
processor (Dage-MTI, Michigan City, Ind., USA) was used
for image enhancement and the Win TV2000 (Hauppage
ComputerWorks, Hauppage, N.Y., USA) software was used
to capture images to a computer. The fluorescence intensity
of the cells was obtained using a GFP filter set (Semrok,
Rochester, N.Y., USA). Image analysis was performed
using Image Pro Plus 6.2 (Media Cybernetics, Bethesda,
Md., USA). We used the achroplan 20× objective, and the
average fluorescence intensity was calculated in one field of
observation as the number of pixels representing tumor cell
area with intensity above backround level (which was
chosen as 45 on an arbitrary gray-scale between 0 and 255)
divided by the number of pixels representing the total
tumor cell area. Electronic cell counting and analysis of cell
survival was performed after observation by using a
NucleoCounter (Chemothec, Allerød, Denmark).
Statistical analysis
Statistical analysis was performed using a statistical
software package (SigmaStat, Jandel Scientific, USA) and
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tests. For all tests, p values smaller than 5% were
considered significant. Data was presented as mean ±
standard error of the mean (SEM).
Flow cytometry
The cells were stored at −20°C until analysis. After
thawing, centrifugation, removal of medium, and resuspen-
sion, the cells were stained with propridium iodide (PI).
The samples were analyzed using a FACSCalibur flow
cytometer (BD Biosciences, San Jose, Calif., USA)
equipped with an argon ion laser. PI-stained cells were
analyzed using an excitation wavelength of 488 nm. The
Cell Quest Pro software was used for data acquisition and
analysis. The distribution of the cell cycle phases was
determined by applying the ModFit Lt 3.1 software (Verity
Software House, Topsham, Me., USA).
Results
Uptake of 2-NBDG
For all of the cell lines, the uptake of 2-NBDG was well
visualized and heterogeneous within the samples. The
benign cell line exhibited a low uptake of 2-NBDG
throughout the experiment. For the tumor cells exposed to
cisplatin, the uptake of 2-NBDG increased over time (days
1–6), as opposed to the untreated control cells, where the
uptake remained constant at a moderately elevated level.
The level of 2-NBDG uptake was correlated to the
previously known sensitivity to cisplatin, with the more
sensitive cell line showing the highest 2-NBDG uptake. We
also observed that the higher the dose of cisplatin, the
higher the uptake of 2-NBDG. The difference in 2-NBDG
uptake was present already at day 1, in the cell line most
sensitive to cisplatin, and from day 3 in both of the other
tumor cell lines (Fig. 1). Visually, the early increase in
uptake of 2-NBDG was most pronounced in pre-apoptotic
cells, exhibiting characteristically rounded shapes and
cytoplasmic vacuoles. Examples are seen in Fig. 2.A s
expected, cell survival following exposure to cisplatin
varied between the SCC cell lines, with the more sensitive
cell lines, LU-HNxSCC-7 and LU-HNxSCC-24, demon-
strating a higher degree of cell death than the less sensitive
cell line. The latter cell line, the LU-CX-2, was not affected
by a cisplatin dose of 10 µM (see Fig. 3).
Cell cycle analysis
With flow cytometry, we found that cisplatin exposure of
the tumor cells resulted in an accumulation of cells in the S
phase, and subsequent cell cycle arrest in the G2/M phase.
This effect was observed on days 3 and 6, and was more
pronounced after the higher cisplatin dose. The untreated
tumor cells showed a gradually increasing G1 phase over
time and no cell cycle arrest. For the fibroblasts, a brief and
transient accumulation of cells in the S phase and in the G2/
M phase was observed after cisplatin exposure.
Discussion
In this study we have demonstrated that exposure to
cisplatin causes a rise in metabolism in SCC cell lines
compared with the pretreatment metabolism. This early
metabolic flare precedes cell death and is clearly visualized
with fluorescent 2-NBDG with real-time microscopy. A
similar flare reaction after cisplatin exposure was observed
by Aide and co-workers in a longitudinal study of testicular
cancer xenografts evaluated in a micro-PET system with
[
18F]FDG at days 0, 2, 4, and 7. A transient metabolic flare
on day 2 was found and this flare coincided with a rise in
cyclin A and a temporary cell cycle arrest in S-and G2/M-
phase on flow cytometry. At day 7 the flare had subsided
and the level of [
18F]FDG uptake had decreased to below
the pre-therapeutic level and correlated to cell death [8]. It
is reasonable to believe that the pronounced sensitivity to
cisplatin in testicular carcinomas may be the explanation for
the large proportion of apoptotic cells as well as the pre-
apoptotic peak the authors found in the cell cycle analysis.
The cell lines in the present study had a lower sensitivity to
cisplatin compared with a testicular cancer cell line, and the
absence of a pre-apoptotic peak in our cell cycle analysis
was thus not surprising. The accumulation of treated tumor
cells in S- and G2/M-phase is in concordance with the
study by Aide et al. [8]
Antitumor treatment causes cell death by various
mechanisms. In the case of cisplatin, the most important
factor is the induction of DNA damage and apoptosis [13].
Pre-apoptotic cells have an increased [
18F]FDG metabolism
compared with nondamaged cells [14], as the apoptotic
process requires high amounts of adenosine-5′-triphosphate
(ATP) [15]. The possibility of a passive influx of [
18F]FDG
over a damaged cell membrane cannot be ruled out, but this
would also lead to a visual flare equally predictive of cell
death. The explanatory model, where lethally damaged cells
show a metabolic flare due to pre-apoptotic changes, is
further supported by the fact that an early metabolic flare
has also been identified following radiotherapy, albeit this
is not an apoptotic cell death. Furuta et al. [16] investigated
the [
18F]FDG accumulation in nude mice bearing ependy-
moblastoma, small cell lung cancer, and glioblastoma at 2,
4, and 6 h after a single radiotherapy dose of 10 Gy. A
transient flare in FDG-uptake was observed after 2 h in the
Nucl Med Mol Imaging (2010) 44:165–169 167most radiosensitive of the tumors, the ependymoblastoma,
whereas the less radiosensitive tumors showed no rise in
[
18F] FDG uptake during the observation time. This
corroborates the fact that the flare is more obvious where
the treatment effect is stronger and thus may be an early
predictive sign of treatment effect.
We undertook this study to elucidate early metabolic
changes during cytotoxic therapy with predictive, on-
therapy clinical studies in mind. Issues are often raised that
false-positive findings due to reactive and inflammatory
changes will lead to misjudgments in [
18F]FDG-PET
studies carried out during or closely after therapy. The
related fear of misinterpreting treatment results has led to
recommendations that at least 6–12 weeks should elapse
before post-treatment scans may be performed for therapy
response assessment [17, 18]. The discussion of glucose
analogue uptake in surrounding tissue is of great interest. In
their study on testicular cancer xenografts, Aide et al. [8]
found a constant level of macrophage infiltration on days
0–4, and thus the presence of reactive cells was not
responsible for the observed metabolic flare which is also
in agreement with our previous results from an HNSCC
xenograft model subjected to cisplatin and investigated with
phosphor imaging and histopathology at days 1, 2, 5, and
8[ 10]. In the present study, the fibroblasts showed a
consistent low uptake of 2-NBDG, suggesting that the
tumor stroma is not a major source of hypermetabolism.
Our findings are supported by data presented by Farace et
al. [19], who observed in a study on xenografts of prostate
Fig. 3 Cell survival day 3 in relation to cisplatin
Fig. 2 Examples of visible flare over time. Fluorescence (top) and
light (bottom) images of the cell lines LU-HNxSCC-7 and LU-CX-2
at days 1, 3, and 6 after exposure to 50 μM cisplatin. A marked uptake
of 2-NBDG was visible in pre-apoptotic cells. The bar at the top right
indicates 10 µm
Fig. 1 Fluorescence as a marker
of 2-NBDG uptake over time
after exposure to different doses
of cisplatin. The results are
relative within each cell line.
Mean values and SEM are
shown (AU arbitrary units)
168 Nucl Med Mol Imaging (2010) 44:165–169and pancreatic cancer that the tumor stroma as well as the
tumor cells adjacent to the stroma and adjacent to blood
vessels exhibited a low [
18F]FDG avidity.
Interestingly, not only a metabolic flare seems to occur
early after cytotoxic treatment but also an increased rate of
proliferation has been observed in responding tumors.
Everitt et al. [20] reported the case of a patient with non-
small cell lung cancer in which the tumor showed a flare of
the proliferation marker 3′-deoxy-3′-[
18F]fluoro-L-thymi-
dine ([
18F]FLT) after 2 Gy of radiotherapy. The flare was
subsequently followed by a decrease in [
18F]FLT uptake
below the baseline level, interpreted as a sign of tumor
response to treatment.
Conclusion
We have demonstrated a metabolic flare as an early sign,
within days of response to cytotoxic treatment, as visualized
with 2-NBDG uptake. Understanding the underlying biolog-
ical properties of this flare will expand the knowledge of
treatment response and sensitivity, and consequentially the
interpretation of the [
18F]FDG-PET scan. Potentially, it could
thus be used as an early marker of treatment sensitivity.
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